This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving treatment with a targeted agent such as gefitinib, erlotinib and icotinib.
Description: progression-free survivalMeasure: PFS Time: 2 years
Description: overall survivalMeasure: OS Time: 3 year
There is one SNP
exon 19 deletion or exon 21 L858R) 10. --- L858R ---